Navigation Links
Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Date:1/29/2008

combination therapy study. We look forward to learning more about bavituximab's potential in this important indication in the coming months as we advance both this study and a second breast cancer trial evaluating a different combination therapy regimen."

Tumor response in this Phase II study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct two additional Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include a second breast cancer protocol assessing bavituximab in combination with carboplatin plus paclitaxel and a non-small cell lung cancer protocol assessing bavituximab in combination with carboplatin and paclitaxel. Bavituxima
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)... Abnormalities in audito...ldren with autism spectrum disorder by using magne...ented today at the annual meeting of the Radiologi...sing MEG, we can record the tiny magnetic fields a...mothy Roberts, Ph.D., vice chair of research in th...
(Date:11/28/2008)...v. 28 Eli Lilly and Comp... New Drug Application (sNDA) from,the U.S. Food a...xetine HCl),for the management of chronic pain. L...st half of 2009, adding data from a recently compl...n of the knee. , The decision does not affe...
(Date:11/26/2008)..., Nov. 26 Children whos...nificantly increased risk of developing mental ill... a Mayo Clinic study published this month in Pedia...my of Pediatrics. , , The retrospective stu...th strabismus (misaligned eyes) and compared them ...
(Date:11/26/2008)...o 406 Subjects , , FRANKLIN, Mass., Nov. 26...ulletin Board: PLCSF) announced today that it has ... Administration (FDA) for its U.S. pivotal trial t...ard System(TM) and associated therapy in the prev... , The FDA also approved PLC,s request to expa...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4American Legacy Foundation Comments on New York State Department of Health Petition to the FDA to Expand Consumer Access to Over the Counter Nicotine 10264 1American Legacy Foundation Comments on New York State Department of Health Petition to the FDA to Expand Consumer Access to Over the Counter Nicotine 10264 2Regular marijuana use increases risk of hepatitis C related liver damage 10262 1Regular marijuana use increases risk of hepatitis C related liver damage 10262 2Regular marijuana use increases risk of hepatitis C related liver damage 10262 3CDC Report Highlights the Need for Safe Use and Safekeeping of Medicines 10260 1CDC Report Highlights the Need for Safe Use and Safekeeping of Medicines 10260 2ActivBiotics Completes Sale of Fixed Assets 3B Expands Due Diligence Initiative for the Sale of Intellectual Property Including Drug Product Candidat 2778 1
...ire/ -- MAP,Pharmaceuticals, Inc. today announced ...se Budesonide (UDB) pediatric asthma therapy,clini...fi Kirdar,Convention and Exhibition Center in Ista...ntitled, "Efficacy and safety,of a novel submicron...delivery in a 6 week study in 1-18 year old asthma...
... tumor lysate,triggers robust antigen-specific CTL..., June 22, 2007,/PRNewswire/ -- MaxCyte, Inc. and ...tion at the 13th Annual Meeting of the,Internation...ing,held June 24-27, 2007 in Sydney, Australia. , ...ture dendritic,cells with tumor lysate triggers ro...
Other Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3
(Date:12/1/2008)...- Media entrepreneur, television and,radio host R...ropist John,Bendheim will be honored by the Cedar...To A Cure" Gala, December 2, 2008, at the Hyatt Re... of the Board of Governors, co-chairs the,event w...olomon. The "Road To,A Cure" Gala is sponsored b...
(Date:12/1/2008)...cy,s goals, commitment and resources , ...o criticism that it has done a poor job safeguardi...g Administration released a report Monday detailin... most important changes in 2008 was the agency,s i... and local health departments to protect the food ...
(Date:12/1/2008)...wire/ -- Due to the urgent need to disseminate aut...search and clinical care, publisher Mary Ann Lie...to all archival online issues of the company,s AID... World AIDS Day. Free online access is available f....com/apc ) and AIDS Research and Human Retroviru...
(Date:12/1/2008)...irstCall/ -- Senetek PLC,(OTC Bulletin Board: SNK...opment of technologies that target the science of ...p AG, specialists in the fields of strategic,deve...h offices in Zurich,Bern and Geneva has publishe...esearch Report, available in the "Investors" secti...
Breaking Medicine News(10 mins):Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
... have found out that Methicillin-resistant Staphyl...e// who before had no established risk factors for...RSA infections, and reviewing their medical record...these infections are acquired from the community. ...
...y on child behavior had pointed out that excessive... might make the child indulge in bullying behavior...peatedly harasses and attacks other children. Bull...physical attack on others or by verbal assaults, t...
...s at Institute of Bioinformatics (Bangalore) had m...omosome// with its transcriptome and proteome sequ...uman X chromosome has a gene density less than oth...oding regions and 696 known genes. The researcher...
...was conducted to find out effective treatment for ...both knees. // The treatment tested was providing...and one third patch on the back of the affected kn...ix weeks of treatment majority of the group of peo...
Other Medicine News:
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: